Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients.
DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).
Exercise and quality of life in women with multiple sclerosis.
Placebo? no thanks, it might be bad for me!
Four Square Step Test in ambulant persons with multiple sclerosis: validity, reliability, and responsiveness.
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Biologics at Novartis
The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
RORγt(+) cells selectively express redundant cation channels linked to the Golgi apparatus.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
A controlled trial of natalizumab for relapsing multiple sclerosis.
Disease-modifying drugs for multiple sclerosis and JC virus expression.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Disease-modifying therapies in Chinese children with multiple sclerosis.
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
Oligodendrocytes Enforce Immune Tolerance of the Uninfected Brain by Purging the Peripheral Repertoire of Autoreactive CD8(+) T Cells.
Structure and Activity of the Acid Sensing Ion Channels.
Fatigue in multiple sclerosis - A brief review.
Absence of mannose-binding lectin in a female with relapsing-remitting multiple sclerosis.
Magnetic Resonance Spectroscopy Markers of Disease Progression in Multiple Sclerosis.
Pages
« first
‹ previous
…
159
160
161
162
163
164
165
166
167
…
next ›
last »